FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:TXNRD2-HMOX1 (FusionGDB2 ID:94984)

Fusion Gene Summary for TXNRD2-HMOX1

check button Fusion gene summary
Fusion gene informationFusion gene name: TXNRD2-HMOX1
Fusion gene ID: 94984
HgeneTgene
Gene symbol

TXNRD2

HMOX1

Gene ID

10587

3162

Gene namethioredoxin reductase 2heme oxygenase 1
SynonymsGCCD5|SELZ|TR|TR-BETA|TR3|TRXR2HMOX1D|HO-1|HSP32|bK286B10
Cytomap

22q11.21

22q12.3

Type of geneprotein-codingprotein-coding
Descriptionthioredoxin reductase 2, mitochondrialselenoprotein Zthioredoxin reductase 3thioredoxin reductase TR3thioredoxin reductase betaheme oxygenase 1heat shock protein, 32-kDheme oxygenase (decycling) 1
Modification date2020031320200313
UniProtAcc.

P09601

Ensembl transtripts involved in fusion geneENST00000400521, ENST00000400519, 
ENST00000535882, ENST00000334363, 
ENST00000400518, ENST00000542719, 
ENST00000491939, 		ENST00000216117, 
Fusion gene scores* DoF score7 X 6 X 5=2104 X 5 X 5=100
# samples 76
** MAII scorelog2(7/210*10)=-1.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(6/100*10)=-0.736965594166206
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: TXNRD2 [Title/Abstract] AND HMOX1 [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointTXNRD2(19929224)-HMOX1(35782678), # samples:2
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneHMOX1

GO:0006788

heme oxidation

17915953

TgeneHMOX1

GO:0035094

response to nicotine

18205746

TgeneHMOX1

GO:0042167

heme catabolic process

17915953

TgeneHMOX1

GO:0045766

positive regulation of angiogenesis

21788589

TgeneHMOX1

GO:0048661

positive regulation of smooth muscle cell proliferation

17600318

TgeneHMOX1

GO:0048662

negative regulation of smooth muscle cell proliferation

17600318

TgeneHMOX1

GO:0055072

iron ion homeostasis

17915953


check buttonFusion gene breakpoints across TXNRD2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across HMOX1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4GBMTCGA-28-5207-01ATXNRD2chr22

19929224

-HMOX1chr22

35782678

+
ChimerDB4GBMTCGA-28-5207-01ATXNRD2chr22

19929224

-HMOX1chr22

35782678

+


Top

Fusion Gene ORF analysis for TXNRD2-HMOX1

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
In-frameENST00000400521ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+
In-frameENST00000400519ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+
In-frameENST00000535882ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+
In-frameENST00000334363ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+
intron-3CDSENST00000400518ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+
intron-3CDSENST00000542719ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+
intron-3CDSENST00000491939ENST00000216117TXNRD2chr22

19929224

-HMOX1chr22

35782678

+

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000400521TXNRD2chr2219929224-ENST00000216117HMOX1chr2235782678+1449110110832240
ENST00000400519TXNRD2chr2219929224-ENST00000216117HMOX1chr2235782678+1442103103825240
ENST00000535882TXNRD2chr2219929224-ENST00000216117HMOX1chr2235782678+1442103103825240
ENST00000334363TXNRD2chr2219929224-ENST00000216117HMOX1chr2235782678+1443104104826240

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000400521ENST00000216117TXNRD2chr2219929224-HMOX1chr2235782678+0.0053113390.99468863
ENST00000400519ENST00000216117TXNRD2chr2219929224-HMOX1chr2235782678+0.005988470.99401146
ENST00000535882ENST00000216117TXNRD2chr2219929224-HMOX1chr2235782678+0.005988470.99401146
ENST00000334363ENST00000216117TXNRD2chr2219929224-HMOX1chr2235782678+0.0058833720.99411666

Top

Fusion Genomic Features for TXNRD2-HMOX1


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)
TXNRD2chr2219929223-HMOX1chr2235782677+1.29E-070.9999999
TXNRD2chr2219929223-HMOX1chr2235782677+1.29E-070.9999999

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for TXNRD2-HMOX1


check button Go to

FGviewer for the breakpoints of chr22:19929224-chr22:35782678

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.HMOX1

P09601

FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.FUNCTION: Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneTXNRD2chr22:19929224chr22:35782678ENST00000400521-11841_7034.333333333333336625.6666666666666Nucleotide bindingFAD


Top

Fusion Gene Sequence for TXNRD2-HMOX1


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>In-frame_ENST00000400521_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(transcript)=1449nt_BP=110nt
CACGACGATGGCGGCAATGGCGGTGGCGCTGCGGGGATTAGGAGGGCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTGCGGGG
CGCGGCGCGGGGCGCAGCAGCTGGTGATGGCCTCCCTGTACCACATCTATGTGGCCCTGGAGGAGGAGATTGAGCGCAACAAGGAGAGCC
CAGTCTTCGCCCCTGTCTACTTCCCAGAAGAGCTGCACCGCAAGGCTGCCCTGGAGCAGGACCTGGCCTTCTGGTACGGGCCCCGCTGGC
AGGAGGTCATCCCCTACACACCAGCCATGCAGCGCTATGTGAAGCGGCTCCACGAGGTGGGGCGCACAGAGCCCGAGCTGCTGGTGGCCC
ACGCCTACACCCGCTACCTGGGTGACCTGTCTGGGGGCCAGGTGCTCAAAAAGATTGCCCAGAAAGCCCTGGACCTGCCCAGCTCTGGCG
AGGGCCTGGCCTTCTTCACCTTCCCCAACATTGCCAGTGCCACCAAGTTCAAGCAGCTCTACCGCTCCCGCATGAACTCCCTGGAGATGA
CTCCCGCAGTCAGGCAGAGGGTGATAGAAGAGGCCAAGACTGCGTTCCTGCTCAACATCCAGCTCTTTGAGGAGTTGCAGGAGCTGCTGA
CCCATGACACCAAGGACCAGAGCCCCTCACGGGCACCAGGGCTTCGCCAGCGGGCCAGCAACAAAGTGCAAGATTCTGCCCCCGTGGAGA
CTCCCAGAGGGAAGCCCCCACTCAACACCCGCTCCCAGGCTCCGCTTCTCCGATGGGTCCTTACACTCAGCTTTCTGGTGGCGACAGTTG
CTGTAGGGCTTTATGCCATGTGAATGCAGGCATGCTGGCTCCCAGGGCCATGAACTTTGTCCGGTGGAAGGCCTTCTTTCTAGAGAGGGA
ATTCTCTTGGCTGGCTTCCTTACCGTGGGCACTGAAGGCTTTCAGGGCCTCCAGCCCTCTCACTGTGTCCCTCTCTCTGGAAAGGAGGAA
GGAGCCTATGGCATCTTCCCCAACGAAAAGCACATCCAGGCAATGGCCTAAACTTCAGAGGGGGCGAAGGGATCAGCCCTGCCCTTCAGC
ATCCTCAGTTCCTGCAGCAGAGCCTGGAAGACACCCTAATGTGGCAGCTGTCTCAAACCTCCAAAAGCCCTGAGTTTCAAGTATCCTTGT
TGACACGGCCATGACCACTTTCCCCGTGGGCCATGGCAATTTTTACACAAACCTGAAAAGATGTTGTGTCTTGTGTTTTTGTCTTATTTT
TGTTGGAGCCACTCTGTTCCTGGCTCAGCCTCAAATGCAGTATTTTTGTTGTGTTCTGTTGTTTTTATAGCAGGGTTGGGGTGGTTTTTG
AGCCATGCGTGGGTGGGGAGGGAGGTGTTTAACGGCACTGTGGCCTTGGTCTAACTTTTGTGTGAAATAATAAACAACATTGTCTGATAG

>In-frame_ENST00000400521_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(amino acids)=240AA_start in transcript=110_stop in transcript=832
MVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYL
GDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQ

--------------------------------------------------------------
>In-frame_ENST00000400519_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(transcript)=1442nt_BP=103nt
ATGGCGGCAATGGCGGTGGCGCTGCGGGGATTAGGAGGGCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTGCGGGGCGCGGCG
CGGGGCGCAGCAGCTGGTGATGGCCTCCCTGTACCACATCTATGTGGCCCTGGAGGAGGAGATTGAGCGCAACAAGGAGAGCCCAGTCTT
CGCCCCTGTCTACTTCCCAGAAGAGCTGCACCGCAAGGCTGCCCTGGAGCAGGACCTGGCCTTCTGGTACGGGCCCCGCTGGCAGGAGGT
CATCCCCTACACACCAGCCATGCAGCGCTATGTGAAGCGGCTCCACGAGGTGGGGCGCACAGAGCCCGAGCTGCTGGTGGCCCACGCCTA
CACCCGCTACCTGGGTGACCTGTCTGGGGGCCAGGTGCTCAAAAAGATTGCCCAGAAAGCCCTGGACCTGCCCAGCTCTGGCGAGGGCCT
GGCCTTCTTCACCTTCCCCAACATTGCCAGTGCCACCAAGTTCAAGCAGCTCTACCGCTCCCGCATGAACTCCCTGGAGATGACTCCCGC
AGTCAGGCAGAGGGTGATAGAAGAGGCCAAGACTGCGTTCCTGCTCAACATCCAGCTCTTTGAGGAGTTGCAGGAGCTGCTGACCCATGA
CACCAAGGACCAGAGCCCCTCACGGGCACCAGGGCTTCGCCAGCGGGCCAGCAACAAAGTGCAAGATTCTGCCCCCGTGGAGACTCCCAG
AGGGAAGCCCCCACTCAACACCCGCTCCCAGGCTCCGCTTCTCCGATGGGTCCTTACACTCAGCTTTCTGGTGGCGACAGTTGCTGTAGG
GCTTTATGCCATGTGAATGCAGGCATGCTGGCTCCCAGGGCCATGAACTTTGTCCGGTGGAAGGCCTTCTTTCTAGAGAGGGAATTCTCT
TGGCTGGCTTCCTTACCGTGGGCACTGAAGGCTTTCAGGGCCTCCAGCCCTCTCACTGTGTCCCTCTCTCTGGAAAGGAGGAAGGAGCCT
ATGGCATCTTCCCCAACGAAAAGCACATCCAGGCAATGGCCTAAACTTCAGAGGGGGCGAAGGGATCAGCCCTGCCCTTCAGCATCCTCA
GTTCCTGCAGCAGAGCCTGGAAGACACCCTAATGTGGCAGCTGTCTCAAACCTCCAAAAGCCCTGAGTTTCAAGTATCCTTGTTGACACG
GCCATGACCACTTTCCCCGTGGGCCATGGCAATTTTTACACAAACCTGAAAAGATGTTGTGTCTTGTGTTTTTGTCTTATTTTTGTTGGA
GCCACTCTGTTCCTGGCTCAGCCTCAAATGCAGTATTTTTGTTGTGTTCTGTTGTTTTTATAGCAGGGTTGGGGTGGTTTTTGAGCCATG
CGTGGGTGGGGAGGGAGGTGTTTAACGGCACTGTGGCCTTGGTCTAACTTTTGTGTGAAATAATAAACAACATTGTCTGATAGTAGCTTG

>In-frame_ENST00000400519_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(amino acids)=240AA_start in transcript=103_stop in transcript=825
MVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYL
GDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQ

--------------------------------------------------------------
>In-frame_ENST00000535882_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(transcript)=1442nt_BP=103nt
ATGGCGGCAATGGCGGTGGCGCTGCGGGGATTAGGAGGGCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTGCGGGGCGCGGCG
CGGGGCGCAGCAGCTGGTGATGGCCTCCCTGTACCACATCTATGTGGCCCTGGAGGAGGAGATTGAGCGCAACAAGGAGAGCCCAGTCTT
CGCCCCTGTCTACTTCCCAGAAGAGCTGCACCGCAAGGCTGCCCTGGAGCAGGACCTGGCCTTCTGGTACGGGCCCCGCTGGCAGGAGGT
CATCCCCTACACACCAGCCATGCAGCGCTATGTGAAGCGGCTCCACGAGGTGGGGCGCACAGAGCCCGAGCTGCTGGTGGCCCACGCCTA
CACCCGCTACCTGGGTGACCTGTCTGGGGGCCAGGTGCTCAAAAAGATTGCCCAGAAAGCCCTGGACCTGCCCAGCTCTGGCGAGGGCCT
GGCCTTCTTCACCTTCCCCAACATTGCCAGTGCCACCAAGTTCAAGCAGCTCTACCGCTCCCGCATGAACTCCCTGGAGATGACTCCCGC
AGTCAGGCAGAGGGTGATAGAAGAGGCCAAGACTGCGTTCCTGCTCAACATCCAGCTCTTTGAGGAGTTGCAGGAGCTGCTGACCCATGA
CACCAAGGACCAGAGCCCCTCACGGGCACCAGGGCTTCGCCAGCGGGCCAGCAACAAAGTGCAAGATTCTGCCCCCGTGGAGACTCCCAG
AGGGAAGCCCCCACTCAACACCCGCTCCCAGGCTCCGCTTCTCCGATGGGTCCTTACACTCAGCTTTCTGGTGGCGACAGTTGCTGTAGG
GCTTTATGCCATGTGAATGCAGGCATGCTGGCTCCCAGGGCCATGAACTTTGTCCGGTGGAAGGCCTTCTTTCTAGAGAGGGAATTCTCT
TGGCTGGCTTCCTTACCGTGGGCACTGAAGGCTTTCAGGGCCTCCAGCCCTCTCACTGTGTCCCTCTCTCTGGAAAGGAGGAAGGAGCCT
ATGGCATCTTCCCCAACGAAAAGCACATCCAGGCAATGGCCTAAACTTCAGAGGGGGCGAAGGGATCAGCCCTGCCCTTCAGCATCCTCA
GTTCCTGCAGCAGAGCCTGGAAGACACCCTAATGTGGCAGCTGTCTCAAACCTCCAAAAGCCCTGAGTTTCAAGTATCCTTGTTGACACG
GCCATGACCACTTTCCCCGTGGGCCATGGCAATTTTTACACAAACCTGAAAAGATGTTGTGTCTTGTGTTTTTGTCTTATTTTTGTTGGA
GCCACTCTGTTCCTGGCTCAGCCTCAAATGCAGTATTTTTGTTGTGTTCTGTTGTTTTTATAGCAGGGTTGGGGTGGTTTTTGAGCCATG
CGTGGGTGGGGAGGGAGGTGTTTAACGGCACTGTGGCCTTGGTCTAACTTTTGTGTGAAATAATAAACAACATTGTCTGATAGTAGCTTG

>In-frame_ENST00000535882_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(amino acids)=240AA_start in transcript=103_stop in transcript=825
MVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYL
GDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQ

--------------------------------------------------------------
>In-frame_ENST00000334363_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(transcript)=1443nt_BP=104nt
GATGGCGGCAATGGCGGTGGCGCTGCGGGGATTAGGAGGGCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTGCGGGGCGCGGC
GCGGGGCGCAGCAGCTGGTGATGGCCTCCCTGTACCACATCTATGTGGCCCTGGAGGAGGAGATTGAGCGCAACAAGGAGAGCCCAGTCT
TCGCCCCTGTCTACTTCCCAGAAGAGCTGCACCGCAAGGCTGCCCTGGAGCAGGACCTGGCCTTCTGGTACGGGCCCCGCTGGCAGGAGG
TCATCCCCTACACACCAGCCATGCAGCGCTATGTGAAGCGGCTCCACGAGGTGGGGCGCACAGAGCCCGAGCTGCTGGTGGCCCACGCCT
ACACCCGCTACCTGGGTGACCTGTCTGGGGGCCAGGTGCTCAAAAAGATTGCCCAGAAAGCCCTGGACCTGCCCAGCTCTGGCGAGGGCC
TGGCCTTCTTCACCTTCCCCAACATTGCCAGTGCCACCAAGTTCAAGCAGCTCTACCGCTCCCGCATGAACTCCCTGGAGATGACTCCCG
CAGTCAGGCAGAGGGTGATAGAAGAGGCCAAGACTGCGTTCCTGCTCAACATCCAGCTCTTTGAGGAGTTGCAGGAGCTGCTGACCCATG
ACACCAAGGACCAGAGCCCCTCACGGGCACCAGGGCTTCGCCAGCGGGCCAGCAACAAAGTGCAAGATTCTGCCCCCGTGGAGACTCCCA
GAGGGAAGCCCCCACTCAACACCCGCTCCCAGGCTCCGCTTCTCCGATGGGTCCTTACACTCAGCTTTCTGGTGGCGACAGTTGCTGTAG
GGCTTTATGCCATGTGAATGCAGGCATGCTGGCTCCCAGGGCCATGAACTTTGTCCGGTGGAAGGCCTTCTTTCTAGAGAGGGAATTCTC
TTGGCTGGCTTCCTTACCGTGGGCACTGAAGGCTTTCAGGGCCTCCAGCCCTCTCACTGTGTCCCTCTCTCTGGAAAGGAGGAAGGAGCC
TATGGCATCTTCCCCAACGAAAAGCACATCCAGGCAATGGCCTAAACTTCAGAGGGGGCGAAGGGATCAGCCCTGCCCTTCAGCATCCTC
AGTTCCTGCAGCAGAGCCTGGAAGACACCCTAATGTGGCAGCTGTCTCAAACCTCCAAAAGCCCTGAGTTTCAAGTATCCTTGTTGACAC
GGCCATGACCACTTTCCCCGTGGGCCATGGCAATTTTTACACAAACCTGAAAAGATGTTGTGTCTTGTGTTTTTGTCTTATTTTTGTTGG
AGCCACTCTGTTCCTGGCTCAGCCTCAAATGCAGTATTTTTGTTGTGTTCTGTTGTTTTTATAGCAGGGTTGGGGTGGTTTTTGAGCCAT
GCGTGGGTGGGGAGGGAGGTGTTTAACGGCACTGTGGCCTTGGTCTAACTTTTGTGTGAAATAATAAACAACATTGTCTGATAGTAGCTT

>In-frame_ENST00000334363_ENST00000216117_TCGA-28-5207-01A_TXNRD2_chr22_19929224_-_HMOX1_chr22_35782678_length(amino acids)=240AA_start in transcript=104_stop in transcript=826
MVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYL
GDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQ

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for TXNRD2-HMOX1


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for TXNRD2-HMOX1


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgeneHMOX1P09601DB00157NADHSmall moleculeApproved|Nutraceutical
TgeneHMOX1P09601DB00157NADHSmall moleculeApproved|Nutraceutical
TgeneHMOX1P09601DB00157NADHSmall moleculeApproved|Nutraceutical

Top

Related Diseases for TXNRD2-HMOX1


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneTXNRD2C0017612Glaucoma, Open-Angle1CTD_human
HgeneTXNRD2C0033578Prostatic Neoplasms1CTD_human
HgeneTXNRD2C0086132Depressive Symptoms1PSYGENET
HgeneTXNRD2C0271148Secondary Open Angle Glaucoma1CTD_human
HgeneTXNRD2C0339573Glaucoma, Primary Open Angle1CTD_human
HgeneTXNRD2C0340427Familial dilated cardiomyopathy1ORPHANET
HgeneTXNRD2C0376358Malignant neoplasm of prostate1CTD_human
HgeneTXNRD2C4049650Familial Glucocorticoid Deficiency Type 11ORPHANET
HgeneTXNRD2C4054695Familial glucocorticoid deficiency1GENOMICS_ENGLAND
TgeneHMOX1C0035126Reperfusion Injury6CTD_human
TgeneHMOX1C0002152Alloxan Diabetes4CTD_human
TgeneHMOX1C0011853Diabetes Mellitus, Experimental4CTD_human
TgeneHMOX1C0021368Inflammation4CTD_human
TgeneHMOX1C0023893Liver Cirrhosis, Experimental4CTD_human
TgeneHMOX1C0038433Streptozotocin Diabetes4CTD_human
TgeneHMOX1C0011860Diabetes Mellitus, Non-Insulin-Dependent3CTD_human
TgeneHMOX1C0020538Hypertensive disease3CTD_human
TgeneHMOX1C0023895Liver diseases3CTD_human
TgeneHMOX1C0028754Obesity3CTD_human
TgeneHMOX1C0086565Liver Dysfunction3CTD_human
TgeneHMOX1C0270715Degenerative Diseases, Central Nervous System3CTD_human
TgeneHMOX1C0524851Neurodegenerative Disorders3CTD_human
TgeneHMOX1C0751733Degenerative Diseases, Spinal Cord3CTD_human
TgeneHMOX1C0009319Colitis2CTD_human
TgeneHMOX1C0019193Hepatitis, Toxic2CTD_human
TgeneHMOX1C0021655Insulin Resistance2CTD_human
TgeneHMOX1C0022116Ischemia2CTD_human
TgeneHMOX1C0024121Lung Neoplasms2CTD_human
TgeneHMOX1C0024623Malignant neoplasm of stomach2CTD_human
TgeneHMOX1C0038356Stomach Neoplasms2CTD_human
TgeneHMOX1C0242379Malignant neoplasm of lung2CTD_human
TgeneHMOX1C0860207Drug-Induced Liver Disease2CTD_human
TgeneHMOX1C0920563Insulin Sensitivity2CTD_human
TgeneHMOX1C1262760Hepatitis, Drug-Induced2CTD_human
TgeneHMOX1C1708349Hereditary Diffuse Gastric Cancer2CTD_human
TgeneHMOX1C3658290Drug-Induced Acute Liver Injury2CTD_human
TgeneHMOX1C4277682Chemical and Drug Induced Liver Injury2CTD_human
TgeneHMOX1C4279912Chemically-Induced Liver Toxicity2CTD_human
TgeneHMOX1C0002395Alzheimer's Disease1CTD_human
TgeneHMOX1C0002726Amyloidosis1GENOMICS_ENGLAND
TgeneHMOX1C0002878Anemia, Hemolytic1CTD_human
TgeneHMOX1C0002879Anemia, Hemolytic, Acquired1CTD_human
TgeneHMOX1C0002889Anemia, Microangiopathic1CTD_human
TgeneHMOX1C0004096Asthma1CTD_human
TgeneHMOX1C0005779Blood Coagulation Disorders1CTD_human
TgeneHMOX1C0006142Malignant neoplasm of breast1CTD_human
TgeneHMOX1C0007273Carotid Artery Diseases1CTD_human
TgeneHMOX1C0010054Coronary Arteriosclerosis1CTD_human
TgeneHMOX1C0011265Presenile dementia1CTD_human
TgeneHMOX1C0011616Contact Dermatitis1CTD_human
TgeneHMOX1C0011875Diabetic Angiopathies1CTD_human
TgeneHMOX1C0012715Iron Metabolism Disorders1CTD_human
TgeneHMOX1C0013221Drug toxicity1CTD_human
TgeneHMOX1C0016059Fibrosis1CTD_human
TgeneHMOX1C0018273Growth Disorders1CTD_human
TgeneHMOX1C0018800Cardiomegaly1CTD_human
TgeneHMOX1C0018801Heart failure1CTD_human
TgeneHMOX1C0018802Congestive heart failure1CTD_human
TgeneHMOX1C0019054Hemolysis (disorder)1CTD_human
TgeneHMOX1C0019158Hepatitis1CTD_human
TgeneHMOX1C0019212Hepatorenal Syndrome1CTD_human
TgeneHMOX1C0020459Hyperinsulinism1CTD_human
TgeneHMOX1C0020507Hyperplasia1CTD_human
TgeneHMOX1C0022660Kidney Failure, Acute1CTD_human
TgeneHMOX1C0022661Kidney Failure, Chronic1CTD_human
TgeneHMOX1C0023186Learning Disorders1CTD_human
TgeneHMOX1C0023212Left-Sided Heart Failure1CTD_human
TgeneHMOX1C0023290Leishmaniasis, Visceral1CTD_human
TgeneHMOX1C0023903Liver neoplasms1CTD_human
TgeneHMOX1C0024668Mammary Neoplasms, Experimental1CTD_human
TgeneHMOX1C0025945Microangiopathy, Diabetic1CTD_human
TgeneHMOX1C0027626Neoplasm Invasiveness1CTD_human
TgeneHMOX1C0030286Pancreatic Diseases1CTD_human
TgeneHMOX1C0030567Parkinson Disease1CTD_human
TgeneHMOX1C0032285Pneumonia1CTD_human
TgeneHMOX1C0032300Lobar Pneumonia1CTD_human
TgeneHMOX1C0032914Pre-Eclampsia1CTD_human
TgeneHMOX1C0033578Prostatic Neoplasms1CTD_human
TgeneHMOX1C0034067Pulmonary Emphysema1CTD_human
TgeneHMOX1C0034069Pulmonary Fibrosis1CTD_human
TgeneHMOX1C0035309Retinal Diseases1CTD_human
TgeneHMOX1C0036341Schizophrenia1PSYGENET
TgeneHMOX1C0038220Status Epilepticus1CTD_human
TgeneHMOX1C0040053Thrombosis1CTD_human
TgeneHMOX1C0041755Adverse reaction to drug1CTD_human
TgeneHMOX1C0087086Thrombus1CTD_human
TgeneHMOX1C0151744Myocardial Ischemia1CTD_human
TgeneHMOX1C0152020Gastroparesis1CTD_human
TgeneHMOX1C0162309Adrenoleukodystrophy1CTD_human
TgeneHMOX1C0162351Contact hypersensitivity1CTD_human
TgeneHMOX1C0221013Mastocytosis, Systemic1CTD_human
TgeneHMOX1C0221021Microangiopathic hemolytic anemia1CTD_human
TgeneHMOX1C0221227Centriacinar Emphysema1CTD_human
TgeneHMOX1C0235527Heart Failure, Right-Sided1CTD_human
TgeneHMOX1C0235574Intravascular hemolysis1CTD_human
TgeneHMOX1C0264393Panacinar Emphysema1CTD_human
TgeneHMOX1C0270823Petit mal status1CTD_human
TgeneHMOX1C0272203Indolent Systemic Mastocytosis1CTD_human
TgeneHMOX1C0273115Lung Injury1CTD_human
TgeneHMOX1C0276496Familial Alzheimer Disease (FAD)1CTD_human
TgeneHMOX1C0311335Grand Mal Status Epilepticus1CTD_human
TgeneHMOX1C0312854Extravascular Hemolysis1CTD_human
TgeneHMOX1C0345904Malignant neoplasm of liver1CTD_human
TgeneHMOX1C0376358Malignant neoplasm of prostate1CTD_human
TgeneHMOX1C0393734Complex Partial Status Epilepticus1CTD_human
TgeneHMOX1C0494463Alzheimer Disease, Late Onset1CTD_human
TgeneHMOX1C0546126Acute Confusional Senile Dementia1CTD_human
TgeneHMOX1C0577631Carotid Atherosclerosis1CTD_human
TgeneHMOX1C0600178External Carotid Artery Diseases1CTD_human
TgeneHMOX1C0678222Breast Carcinoma1CTD_human
TgeneHMOX1C0750900Alzheimer's Disease, Focal Onset1CTD_human
TgeneHMOX1C0750901Alzheimer Disease, Early Onset1CTD_human
TgeneHMOX1C0750986Internal Carotid Artery Diseases1CTD_human
TgeneHMOX1C0750987Arterial Diseases, Common Carotid1CTD_human
TgeneHMOX1C0751262Adult Learning Disorders1CTD_human
TgeneHMOX1C0751263Learning Disturbance1CTD_human
TgeneHMOX1C0751265Learning Disabilities1CTD_human
TgeneHMOX1C0751522Status Epilepticus, Subclinical1CTD_human
TgeneHMOX1C0751523Non-Convulsive Status Epilepticus1CTD_human
TgeneHMOX1C0751524Simple Partial Status Epilepticus1CTD_human
TgeneHMOX1C0887898Experimental Lung Inflammation1CTD_human
TgeneHMOX1C1112486Aggressive Systemic Mastocytosis1CTD_human
TgeneHMOX1C1257931Mammary Neoplasms, Human1CTD_human
TgeneHMOX1C1257963Endogenous Hyperinsulinism1CTD_human
TgeneHMOX1C1257964Exogenous Hyperinsulinism1CTD_human
TgeneHMOX1C1257965Compensatory Hyperinsulinemia1CTD_human
TgeneHMOX1C1330966Developmental Academic Disorder1CTD_human
TgeneHMOX1C1383860Cardiac Hypertrophy1CTD_human
TgeneHMOX1C1458155Mammary Neoplasms1CTD_human
TgeneHMOX1C1527231Adrenomyeloneuropathy1CTD_human
TgeneHMOX1C1565662Acute Kidney Insufficiency1CTD_human
TgeneHMOX1C1623038Cirrhosis1CTD_human
TgeneHMOX1C1846707SPINOCEREBELLAR ATAXIA 171CTD_human
TgeneHMOX1C1956346Coronary Artery Disease1CTD_human
TgeneHMOX1C1959583Myocardial Failure1CTD_human
TgeneHMOX1C1961112Heart Decompensation1CTD_human
TgeneHMOX1C2350344Chronic Lung Injury1CTD_human
TgeneHMOX1C2350878Focal Emphysema1CTD_human
TgeneHMOX1C2609414Acute kidney injury1CTD_human
TgeneHMOX1C2937358Cerebral Hemorrhage1CTD_human
TgeneHMOX1C3714636Pneumonitis1CTD_human
TgeneHMOX1C4704874Mammary Carcinoma, Human1CTD_human
TgeneHMOX1C4721507Alveolitis, Fibrosing1CTD_human